和黄醫藥 HUTCHMED 2022年 年報 HUTCHMED (CHINA) LIMITED 和黃醫藥(中國)有限公司 ( 於 開曼群島註冊之有限公司) HKEX: 13 | Nasdaq: HCM | AIM: HCM 公司資料 | --- | --- | |----------------------------------------------------------|-------| | | | | 董事會 | | | 執行董事 | | | 杜志強BSc, ACGI, MBA 主席 | | | 蘇慰國BSc, PhD | | | 首席執行官兼首席科學官 | | | 鄭澤鋒BEc, CA | | | 首席財務官 | | | 非執行董事 | | | 艾樂德BA, MA, MA, PhD 施熙德BSE, MA, MA, EdM, Solicitor, | | | FCG(CS, CGP), HKFCG(CS, CGP)(PE) | | | 孫樂非BSc, MA | | | 獨立非執行董事 | | | 卡博樂BA, FCMA | | | 高級獨立董事 | | | 費凱寧MD, BSc | | | 蓆紀倫B ...

Revenue Growth - The comprehensive revenue from the oncology/immunology business increased nearly 4 times to $119.6 million in 2021, with this trend continuing into 2022 [15]. - Total revenue for 2021 increased by 56% to $356.1 million, driven by the commercialization of three self-developed oncology drugs [18]. - Other business revenue grew by 20% (CER: 13%) to $236.5 million in 2021, compared to $197.8 million in 2020 [31]. - The oncology/immunology business revenue for 2021 reached $119.6 million, a 296% increase compared to $30.2 million in 2020, aligning with the revenue guidance of $110 million to $130 million [18]. - The sales of Aiyoute® (Fruquintinib) in China grew by 111% to $71 million in 2021, reflecting strong management performance in medical communication and marketing [18]. - The sales of Vorasatinib® (Savolitinib) reached $15.9 million in 2021, as it became the first selective MET inhibitor in China, quickly gaining market recognition [18]. - The sales of Sunitinib® (Sofitinib) was launched in 2021 for treating neuroendocrine tumors, generating sales of $11.6 million, marking a promising start in the self-pay market [18]. Clinical Development - There are currently over 45 clinical studies ongoing globally, with seven innovative drug candidates undergoing clinical development outside of China [12][15]. - The company has initiated four Phase III studies and one Phase II study for the drug Vorasertib, which received its first approval in 2021, triggering a milestone payment of $40 million [15]. - The NDA application for Surufatinib for the treatment of advanced neuroendocrine tumors is in the late stages of registration review in the EU [15]. - The company has a pipeline of 12 innovative molecular drugs, with three already approved and successfully launched [11][13]. - In 2021, the company initiated several key clinical studies for its drug Savolitinib, including a global Phase III study (NCT05043090) in October for treating MET-driven unresectable and locally advanced or metastatic papillary renal cell carcinoma [23]. - The company plans to initiate a Phase III study (SURTORI-02) in China for the combination therapy of Savolitinib and Tuoyi® for esophageal cancer in the second half of 2022 [24]. - The company has initiated multiple Phase II studies for Furmonertinib in combination with other therapies for advanced or metastatic cancers, including colorectal and gastric cancers [24]. Financial Position - The company has over $1 billion in cash and plans to divest non-core assets to support its strategic initiatives [16]. - Cash and cash equivalents and short-term investments totaled $1.0117 billion as of December 31, 2021, compared to $435.2 million at the end of 2020 [38]. - The company reported a net loss attributable to shareholders of $194.6 million in 2021, compared to a net loss of $125.7 million in 2020, reflecting a 55.0% increase in losses [42]. - The total operating expenses for 2021 were $684.4 million, up from $424.6 million in 2020, indicating a 61.1% increase [42]. - The company’s total assets grew to $1.373 billion in 2021, compared to $724.1 million in 2020, a 89.8% increase [41]. Leadership Changes - The new CEO, Dr. Su Weiguo, has been appointed as part of the succession planning following the retirement of the previous CEO, Mr. He Jun [13][14]. - The company is expanding its leadership team with experienced professionals from the pharmaceutical industry, including former executives from Gilead Sciences and Takeda Pharmaceuticals [142][143]. Research and Development - R&D expenses increased to $299.1 million in 2021 from $174.8 million in 2020, marking a 70.9% growth due to the expansion of innovative oncology drug candidates [39]. - The company continues to prioritize employee development and community engagement through various training programs and initiatives [131]. - The company is focused on enhancing its corporate governance practices, with members holding senior positions in professional accounting and governance bodies [144]. Strategic Partnerships - The company has established a partnership with Hain Celestial for the marketing, distribution, and sales of its products, with pricing based on standard costs plus a profit margin [172]. - The company collaborates with Eli Lilly for fuzuloparib's rights outside of China, enhancing its market reach [64]. Sustainability and Governance - The company aims to enhance its sustainability practices and has established a sustainability committee at the board level [35]. - The company is committed to sustainable development, as indicated by the presence of a dedicated committee chaired by a board member [141]. - The company has a strong emphasis on research and development, particularly in innovative therapies for cancer [143][145]. Shareholder Information - The company reported a total shareholding of 332,574,650 shares, representing approximately 38.46% ownership by CK Hutchison Global Investments Limited [180]. - The company has adopted a share trading code for directors to disclose their interests and holdings [148]. - The company has a stock option plan adopted in 2015, which remains in effect [184].